Lead Product(s): S011806
Therapeutic Area: Dermatology Product Name: S011806
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing August 24, 2021
Proceeds of the financing are expected to be used to support advancement of the Company’s preclinical IL-17 antagonist, S011806 into clinical development, advancement of preclinical α4ß7 and αVß1/αVß6 integrin programs, pipeline expansion and other general corporate purposes.